Skip to content
NYSE · PHARMACEUTICAL PREPARATIONS · LARGE CAP

AbbVie Inc. ABBV

15 fiscal years on record · USD · FY2025 reported · SEC filings only
11 YEARS OF DIVIDEND GROWTH
$61.2B
▲ 8.6% YoY
$4.2B
▼ 1.2% YoY
$17.8B
▼ 0.1% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

AbbVie develops, manufactures, commercializes and sells medicines and therapies, operating as a single global business segment. It employed approximately 57,000 employees in over 70 countries as of December 31, 2025. In 2025, three wholesale distributors (McKesson Corporation, Cardinal Health, Inc. and Cencora, Inc.) accounted for substantially all of its pharmaceutical product sales in the United States. Its product portfolio spans immunology, neuroscience, oncology and aesthetics. In immunology, the company maintains a portfolio across rheumatology, dermatology and gastroenterology. The Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring and skincare products. Incorporated in Delaware on April 10, 2012, AbbVie became an independent, publicly traded company on January 1, 2013, when Abbott Laboratories distributed 100% of the outstanding common stock of AbbVie to Abbott's shareholders.

Written from the business description in AbbVie Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 20 February 2026. Every sentence was checked against that document before publication.

Growth

USD 61.2B
Revenue, FY2025 · full 15-year series below
Revenue $B Net income $B
FY2025 · Revenue 61.2 · Net income 4.2
25.0B50.0B
201120142017202020232025
Compound annual growth
+1.8%
+6.0%
+10.3%
−29.1%
−1.7%
−1.9%
−29.1%
−2.8%
−2.8%
+5.2%
+6.6%
+12.2%
+3.4%
+8.0%
+1.5%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +6.0% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

7 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 24.6% · Net 6.9%
10%20%30%
201120182025
ROE
FY2024 · ROE 62.5%
50%100%150%
201120182025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.

Return on equity has no reading this year — return on capital employed, just below, still does: 16%.

Cash & shareholders

USD 12.5B
returned in FY2025 · dividends + net buybacks
Free cash flow $B
FY2025 · FCF 17.8
10B20B
201120182025
Net buybacks $B Dividends $B
FY2025 · Dividends 11.7 · Net buybacks 0.8
10B20BDividendsNet buybacks
2013201520172019202120232025

USD 11.7B in dividends and USD 808.0M in buybacks — 295% of the year's profit, so the payout drew on cash built up earlier.

Total assetsUSD 134.0B
EquityUSD -3.3B
CashUSD 5.2B
Gross debtUSD 67.0B
Net debtUSD 61.8B
Current ratio0.67×

Equity was zero or negative — liabilities equaled or exceeded assets. No ratio is shown.

The 15-year record

15 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
ABBV, 15-year financial record
Metric 202520242023202220212020201920182017201620152014201320122011
Revenue $B61.256.354.358.156.245.833.332.828.225.622.920.018.818.417.4
Operating income $B15.19.112.818.117.911.413.06.49.59.37.53.45.75.83.6
EBITDA $B15.89.913.518.918.712.013.46.910.09.88.03.86.16.34.1
Income tax $B2.4−0.61.41.61.4−1.20.5−0.52.41.91.50.61.20.50.2
Net income $B4.24.34.911.811.54.67.95.75.36.05.11.84.15.33.4
Free cash flow $B17.817.822.124.222.016.812.812.89.46.67.02.95.86.05.9
EPS, diluted $2.362.392.726.636.452.725.283.663.303.633.131.102.563.352.18
Dividend / sh $6.656.295.995.715.314.844.393.952.632.352.101.752.00◌◌
Payout %2762582178580167819877626415062——
ROE %—62.535.272.581.0———109.1138.7180.956.9——◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

Compare

This company against its peers

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 58 reconciliationsAUDITED

Reconciled in 15 of the 15 fiscal years we could check. 10 checks were skipped: the balance sheet is not tagged before 2012. Four checks were skipped: EPS is not tagged before 2011. Four checks were skipped: revenue is not tagged before 2011.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNYSE
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2011

Share this section

Download image